Contact UsCareers
Top bar


Current Partners

Ayala collaborates with companies for the betterment of patients with rare and aggressive cancers.

Our current partners


We obtained an exclusive, worldwide license to develop and commercialize AL101 and AL102 from Bristol-Myers Squibb Company, or BMS, in November 2017.


We are collaborating with Novartis International Pharmaceutical Limited, or Novartis, to develop AL102 for the treatment of multiple myeloma, or MM, in combination with Novartis’ B-cell maturation antigen, or BCMA, targeting therapies, since 2018.


We are collaborating with ArcherDX to co-develop a suitable diagnostic test that test for all four genes including mutations and fusions, since 2019.